Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Alnylam Pharmaceuticals Inc’s current trading price is -2.85% away from its 52-week high, while its distance from the 52-week low is 120.71%. The stock’s price range over this period has fluctuated between $205.87 and $467.71. The company, operating within the financial sector, had a trading volume of approximately 1.08 million for the day, which was noticeably higher than the average daily share volume of 1.06 million over the last 3 months.
The stock price for Alnylam Pharmaceuticals Inc (ALNY) currently stands at $454.38. The stock experienced a substantial increase in the last session, hitting $570.0 after starting at $454.38. The stock’s lowest price was $236.0 before closing at $467.55.
In terms of market performance, Alnylam Pharmaceuticals Inc had a fairly even. The highest value for the stock in the past year was $467.71 on 08/22/25, and the lowest value was recorded at $205.87 on 04/09/25.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Alnylam Pharmaceuticals Inc (ALNY) has experienced a quarterly rise of 57.22% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 59.56B and boasts a workforce of 2230 employees.
Alnylam Pharmaceuticals Inc: What Analysts Are Saying
As of right now, 16 analysts are rating Alnylam Pharmaceuticals Inc as a BUY, 8 of the polled analysts branded the stock as an OVERWEIGHT, 7 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 313.77, with a change in price of +184.36. Similarly, Alnylam Pharmaceuticals Inc recorded 1,060,577 in trading volume during the last 100 days, posting a change of +68.28%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for ALNY stands at 10.93. Similarly, the long-term debt-to-equity ratio is also 10.36.
ALNY Stock Stochastic Average
Today’s raw stochastic average for Alnylam Pharmaceuticals Inc over the last 50 days is 91.13%.This indicates a increase from the raw stochastic average of the past 20 days, which was 89.44%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 94.57% and 96.12%, respectively.
ALNY Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. This year’s metric has recorded a Price increase of 61.84%. However, over the past six months, we’ve seen a weaker performance of 81.32%. The price of ALNY fallen by 38.53% over the last 30 days. And in the last five days, it has surged by 1.22%.
